Back to top
more

Surgery Partners (SGRY)

(Delayed Data from NSDQ)

$21.62 USD

21.62
1,422,176

-0.41 (-1.86%)

Updated Sep 19, 2025 03:59 PM ET

After-Market: $21.58 -0.04 (-0.19%) 5:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Surgery Partners (SGRY) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Surgery Partners (SGRY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Surgery Partners (SGRY) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 300% and 0.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Surgery Partners (SGRY): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 900% and 3.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Surgery Partners (SGRY) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 28.57% and 2.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Apollo Medical Holdings, Inc. (AMEH) Lags Q4 Earnings Estimates

by Zacks Equity Research

Apollo Medical Holdings, Inc. (AMEH) delivered earnings and revenue surprises of -77.78% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medpace (MEDP) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 19.10% and 2.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Surgery Partners (SGRY) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -150% and 0.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CareDx (CDNA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 2.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Surgery Partners (SGRY) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 0% and 1.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Surgery Partners (SGRY) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Surgery Partners (SGRY) stock based on the movements in the options market lately.

Zacks Equity Research

Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -80% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Surgery Partners (SGRY) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -11.54% and 2.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Predict a 35% Upside in Surgery Partners (SGRY): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 34.6% upside potential for Surgery Partners (SGRY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Surgery Partners (SGRY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ortho Clinical Diagnostics (OCDX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ortho Clinical (OCDX) delivered earnings and revenue surprises of 20% and 0.39%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can Surgery Partners (SGRY) Climb 40% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 39.5% in Surgery Partners (SGRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Rimmi Singhi headshot

Save Your Portfolio by Getting Rid of These 4 Toxic Stocks

by Rimmi Singhi

Investors who can spot the overpriced stocks and shun them at the right time are the ones likely to make a profit. SGRY, ASAI, BLKB and AZTA are a few toxic stocks that you should disown right away.

Zacks Equity Research

Surgery Partners (SGRY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -25.00% and 0.91%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Surgery Partners (SGRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Avantor, Inc. (AVTR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti

by Zacks Equity Research

Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti

Urmimala Biswas headshot

5 Medical Services Stocks Countering Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most. However, falling healthcare spending may disrupt the trend.

Zacks Equity Research

Down 26.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Surgery Partners (SGRY)

by Zacks Equity Research

Surgery Partners (SGRY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.